Metabolic Capacity of Israeli Populations

Hadassah Medical Center

Status: Unknown

Conditions: Healthy Volunteers

Treatments: Drug: Debrisoquine; Drug: Dapsone; Drug: Caffeine; Drug: Mephenytoin

Study type: Interventional

Funder types: Other

Identifiers

NCT00162383

yc19551-HMO-CTIL

Details and patient eligibility

About

The ability to metabolize drugs varies greatly among individuals. Major fraction of this variability lies in genetic polymorphisms of genes encoding for enzymes responsible for both phase I and phase II reactions.

The purpose of this study ws to evaluate the phenotypic activity and the frequency of genetic polymorphisms in different phase II and phase I enzymes among various populations residing in Israel.

Enrollment: 1,200 estimated patients

Sex: All

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age range 20-50
• Absence of significant disease state

Exclusion criteria

• The presence of significant disease states
• The regular use of drugs (including birth control pills)

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,200 participants in 1 patient group

Cocktail

Experimental group

Treatment:

Drug: Dapsone

Drug: Debrisoquine

Drug: Caffeine

Drug: Mephenytoin